• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC | Inspections

New Search Back to Search Results
Note: this medical device record is a supplement. The device description may have changed. Be sure to look at the original PMA to get an up-to-date view of this device.
Classification Namebiologic material, dental
Generic Nameenamel derivative
Regulation Number872.3930
ApplicantBIORA, INC.
PMA NumberP930021
Supplement NumberS005
Date Received07/26/2000
Decision Date06/04/2002
Product Code
NQA[ Registered Establishments with NQA ]
Advisory Committee Dental
Supplement Typenormal 180 day track
Supplement Reason labeling change - other
Expedited Review Granted? No
Combination Product No
Approval Order Statement 
Approval for the revisions to the package insert as listed below based on new data that has been presented in this pma supplement. 1) inclusion of the following statement in the clinical considerations section: "histological studies have demonstrated results ranging from complete periodontal regeneration (newly formed cementum, periodontal ligament, and alveolar bone) to repair including new connective tissue attachment (connective tissue adaptation via new cementum) and a new attachment mediated by an epithelial attachment (long junctional epithelium). The long-term stability of the regenerated tissue has not been established. As in any periodontal surgical therapy, defect morphology, surgical technique and host response are important parameters for successful outcomes. " 2) inclusion of the following statements in the clinical considerations section: a) patients tend to report less post-surgical discomfort; b) clinicians have reported on enhanced wound healing.